Viewing nowCombinationLowbica HCT Tablet 10/40/12.5 Milligrams
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg +1 more
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.

MFDS item code 201900774 · Approved 2019.01.31 · Insurance code 655404050
Treatment of essential hypertension not controlled with combination therapy
This medication is used when blood pressure is not adequately controlled in patients with essential hypertension through combination therapy with amlodipine and olmesartan medoxomil. The actions of the two drugs complement each other to effectively lower and control blood pressure. This helps reduce the risk of complications from hypertension and improves cardiovascular health in patients. This medication is used to support the treatment of hypertension patients more effectively.
Take 1 tablet once daily with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or this medicine 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or this medicine 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or 10/40/12.5mg. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg 5/40/0mg → 5/40/12.5mg → 5/40/25mg 10/40/0mg → 10/40/12.5mg → 10/40/25mg The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (aged 65 years and over) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. In particular, there is very limited experience with the use of this medicine in older adults aged 75 years and over; therefore, monitor them very carefully when administering this medicine.
The safety and efficacy in pediatric patients under 18 years have not been established; use of this medicine is not recommended.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Do not take this medication if you have a history of allergies or hypersensitivity reactions to this medication or any of its components, are pregnant or breastfeeding, have severe hypotension or heart valve disease, have acute heart failure or severe kidney and liver dysfunction. Caution is required for those with low blood volume or electrolyte imbalances as blood pressure may drop rapidly at the onset of treatment, and their condition should be closely monitored during treatment. Patients with impaired kidney function or kidney transplant recipients, those with renovascular hypertension, and those with severe liver dysfunction require special precautions when taking this medication. Since this medication lowers blood pressure, it can cause dizziness; therefore, caution should be exercised when driving or operating machinery. This medication may interact with other drugs, so you must consult with your doctor or pharmacist, especially if you are taking lithium, non-steroidal anti-inflammatory drugs, or other antihypertensive medications. This medication can cause electrolyte imbalances, so it is important to regularly check serum electrolyte levels through blood tests. If breastfeeding, it is recommended to discontinue nursing or stop taking the medication as its components may pass into breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age, so its use is not recommended. Elderly patients are advised to start at a low dose considering the possibility of impaired kidney and liver functions. In the case of overdose, symptoms such as hypotension, palpitations, and dizziness may occur, necessitating immediate medical attention. This medication should be stored in a tightly closed container to protect it from light and moisture, and should be kept out of reach of children; transferring it to another container is to be avoided.
Peripheral edema, headache, dizziness, upper respiratory infection, rhinitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion state, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disorders, orthostatic dizziness, syncope, taste disorder, hypertonia, sensory impairment, dysesthesia, peripheral neuropathy, drowsiness, fainting, convulsions, loss of appetite, tremors, visual disturbances, decreased tears, exacerbation of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular dermatitis, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, hives, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, increased serum creatinine, increased serum urea, increased serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, increased liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, abdominal edema, asthenia, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute deafness, lymphadenitis, acute respiratory distress syndrome
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.
Round film-coated tablets in reddish color
28 tablets (14 tablets/PTP X 2)/box
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg +1 more
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.